Eli Lilly Stock Rockets on GLP‑1 Boom and New Approvals: Is LLY the Next Trillion‑Dollar Pharma Titan?
In‑Depth Report Introduction Eli Lilly and Company (NYSE: LLY) has become the poster‑child for the emerging class of GLP‑1‑based obesity and diabetes therapies. Its injectable tirzepatide products Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management) have delivered explosive growth, propelling the company’s market capitalization into the high‑hundred‑billion range. On 6 Oct 2025, LLY traded around $840, close to its all‑time highs marketbeat.com. The company’s pivot toward metabolic and neurodegenerative diseases, combined with an aggressive manufacturing expansion, has made it one of the most closely watched stocks on Wall Street. Stock Performance and Valuation After an extraordinary rally in late September 2025, LLY opened
